1. Nelson H. American College of Surgeons, Alliance for Clinical Trials in Oncology. Operative standards for cancer surgery. Philadelphia: Wolters Kluwer Health; 2015.
2. Katz MH (ed). Operative Standards for Cancer Surgery: volume 2. American College of Surgeons Clinical Research Program. Philadelphia, PA: Wolters Kluwer; 2019.
3. Noone AMHN, Krapch M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2015. 2018; Bethesda, MD. https://seer.cancer.gov/csr/1975_2015/.
4. Al-Batran S HN, Schmalenberg H, Kopp J, Haag GM, Luley KB. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol. 2017;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.
5. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. https://doi.org/10.1016/s0140-6736(11)61873-4(Epub 2012/01/10).